Enhanced insulin signaling via circulating ATG7: A potential therapeutic strategy for diabetes
- Yi Guan
- Yang Yu
- Mengdi Fu
- Hongde Xu
- Eunyoung Lee
- Hanfeng Wang
- José María Moreno-Navarrete
- Chengsi Deng
- Yuheng Li
- Kangjing Song
- Qiqiang Guo
- Xiaoyou Jiang
- Xiaoyu Song
- Wendong Guo
- Yanling Feng
- Fei Yi
- Ning Bai
- Jiabin Li
- Jingyang Chen
- Wenjing Shen
- Wan Yu
- Difei Wang
- Siru Hou
- Jichun Tan
- Jose Manuel Fernandez-Real
- Antonio Vidal-Puig
- Liu Cao
2025-12-29
Diabetes and insulin resistance (IR) remain major global health challenges, underscoring the need for novel therapeutic strategies. Here, we identify an autophagy-independent role of circulating autophagy-related gene 7 (ATG7) in metabolic regulation. Circulating ATG7 enhances insulin sensitivity and glucose homeostasis by directly interacting with IRS1 and modulating insulin signaling (IS) through liver–muscle crosstalk. Mechanistically, ATG7 binds to IRS1, promoting its activation and the propagation of downstream IS. Notably, we identify an ATG7-derived peptide (Aap2) that recapitulates ATG7’s insulin-sensitizing effects and improves glycemic control in both Type 1 and Type 2 diabetic mouse models. These findings establish ATG7 as a key regulator of IS and suggest that targeting ATG7 may represent a promising therapeutic approach for IR and diabetes.